Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin) - Scorecard - MDSpire

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • By

  • Emma Guttman-Yassky

  • Alan D. Irvine

  • Melinda Gooderham

  • Stephan Weidinger

  • Lynda Spelman

  • Jonathan I. Silverberg

  • Heidi Crane

  • Hany ElMaraghy

  • Louise DeLuca-Carter

  • Maria Lucia Buziqui Piruzeli

  • Georgia Martimianaki

  • Evangeline Pierce

  • Helena Agell

  • Diamant Thaçi

  • June 19, 2026

  • 0 min

Share

Clinical Scorecard: Long-Term Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis Patients: Results from a Three-Year Extension Study (ADjoin)

At a Glance

CategoryDetail
ConditionAtopic Dermatitis (AD)
Key MechanismsLebrikizumab is a monoclonal antibody that binds to interleukin (IL)-13, blocking its downstream effects.
Target PopulationAdults and adolescents 12 years and older with moderate-to-severe AD.
Care SettingClinical trials and long-term treatment settings.

Key Highlights

  • Lebrikizumab demonstrated durable improvement in AD symptoms through 3 years.
  • Safety profile consistent with previously reported data.
  • Long-term treatment supports disease control and quality of life improvement.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis of moderate-to-severe AD based on clinical criteria.

Management

  • Lebrikizumab is recommended as a treatment option for moderate-to-severe AD.

Monitoring & Follow-up

  • Monitor for efficacy and safety during long-term treatment.

Risks

  • Potential for uncontrolled AD in patients not achieving sustained long-term clinical benefit.

Patient & Prescribing Data

Patients with moderate-to-severe AD who have previously completed specific studies.

Lebrikizumab is effective for long-term management of AD symptoms.

Clinical Best Practices

  • Consider lebrikizumab for patients who have not achieved adequate control with other therapies.
  • Assess patient response at week 16 to determine eligibility for continued treatment.

Related Resources & Content

Original Source(s)

Three-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin)

  • by Emma Guttman-Yassky, Alan D. Irvine, Melinda Gooderham, Stephan Weidinger, Lynda Spelman, Jonathan I. Silverberg, Heidi Crane, Hany ElMaraghy, Louise DeLuca-Carter, Maria Lucia Buziqui Piruzeli, Georgia Martimianaki, Evangeline Pierce, Helena Agell, Diamant Thaçi

  • June 19, 2026

Related Content

Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis

Psoriasis–AD Switching May Mimic Treatment Failure

Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.

Case Report: Ivarmacitinib in the treatment of refractory primary cutaneous amyloidosis